Skip to main content

Table 1 Antibacterial activity of the newly synthesized compounds

From: β-Keto esters from ketones and ethyl chloroformate: a rapid, general, efficient synthesis of pyrazolones and their antimicrobial, in silico and in vitro cytotoxicity studies

 

S. aureus

E. coli

P. aeruginosa

K. pneumonia

Compound number

    

1

21 (6.25)

17 (6.25)

18 (6.25)

20 (6.25)

2

20 (6.25)

18 (6.25)

19 (6.25)

21 (6.25)

3

23 (6.25)

19 (6.25)

20 (6.25)

22 (6.25)

4

20 (6.25)

17 (6.25)

18 (6.25)

19 (6.25)

5

16 (100)

17 (100)

12 (100)

14 (100)

6

17 (100)

17 (100)

11 (100)

15 (100)

7

26 (12.5)

23 (12.5)

21 (12.5)

20 (12.5)

8

19 (100)

23 (100)

22 (100)

16 (100)

9

26 (6.25)

23 (6.25)

21 (6.25)

20 (6.25)

10

22 (6.25)

18 (6.25)

19 (6.25)

21 (6.25)

11

17 (6.25)

21 (6.25)

20 (6.25)

21 (6.25)

13

28 (12.5)

22 (12.5)

25 (12.5)

23 (12.5)

14

29 (12.5)

25 (12.5)

22 (12.5)

21 (12.5)

15

23 (6.25)

20 (6.25)

21 (6.25)

22 (6.25)

17

31 (12.5)

25 (12.5)

27 (12.5)

20 (12.5)

19

18 (6.25)

19 (6.25)

22 (6.25)

20 (6.25)

20

24 (6.25)

25 (6.25)

26 (6.25)

26 (6.25)

21

30 (12.5)

24 (12.5)

25 (12.5)

22 (12.5)

23

24 (12.5)

27 (12.5)

24 (12.5)

23 (12.5)

24

16 (100)

17 (100)

12 (100)

14 (100)

25

21 (12.5)

24 (12.5)

26 (12.5)

22 (12.5)

26

21 (6.25)

23 (6.25)

22 (6.25)

20 (6.25)

Ciprofloxacin

23 (6.25)

32 (6.25)

28 (6.25)

24 (6.25)

  1. Zone of inhibition (mm); MIC (μg/mL) given in parenthesis.